LBS-007, a novel targeted therapy, has received FDA fast track designation for the treatment of acute myeloid leukemia.
Melbourne, Victoria, Australia.
LBS-007, a novel targeted therapy, has received FDA fast track designation for the treatment of acute myeloid leukemia.